NewsSource: EClinCloud

Understanding Protocol Deviation Documentation Requirements in Revised GCP and ICH-GCP

4 min readEClinCloud Editorial Team
Article illustration

Source: EClinCloud. Author: EClinCloud.

Article illustration

What is a protocol deviation?

What are the regulatory requirements for documenting protocol deviations?

Article illustration
Article illustration

Definition of Protocol Deviation in Revised GCP/ICH-GCP


Revised GCP

During a clinical trial, any intentional or unintentional departure from or noncompliance with the trial protocol approved by the ethics committee and GCP principles is referred to as a protocol deviation or protocol violation.


ICH-GCP

ICH-GCP stipulates regarding protocol deviations that the investigator/institution should comply with the trial protocol agreed to by the sponsor, approved by the regulatory authorities (if required), and approved by the ethics committee.

Regulatory Requirements for Documenting Protocol Deviations

Article illustration
Article illustration

Requirements in GCP for investigators and sponsors/monitors on handling protocol deviations:

Article illustration
Article illustration


Investigator, Article 20

The investigator or their designated trial staff should document and explain any deviation from the trial protocol. When the investigator modifies or deviates from the trial protocol without prior approval from the ethics committee in order to eliminate an immediate hazard to subjects, the investigator should promptly report the modification or deviation with the reasons to the ethics committee and the sponsor, and to the drug regulatory authorities when necessary.


Sponsor, Article 51

After each monitoring visit, the monitor should promptly submit a written report to the sponsor. The report should include the monitoring date, site, name of the monitor, and names of the investigator and other personnel contacted by the monitor; a summary of the monitoring work, issues identified in the clinical trial and statements of facts, deviations from and deficiencies against the trial protocol, and monitoring conclusions; and a description of corrective actions taken or proposed for issues identified during monitoring, and recommendations to ensure trial compliance with the protocol. The report should provide sufficient detail to allow verification of compliance with the monitoring plan. Centralized monitoring reports may be submitted separately from on-site monitoring reports. The sponsor should review and follow up on issues in the monitoring report and document and retain them.

ICH-GCP requirements for documenting and reporting protocol deviations are:

Article illustration


ICH E3 "Structure and Content of Clinical Study Reports" stipulates:

01 All important protocol deviations related to inclusion/exclusion criteria, protocol conduct, patient management, or assessment should be listed.
02 In the study report, protocol deviations should be appropriately summarized by study site and category, such as: entering the trial without meeting the inclusion criteria, failing to withdraw despite meeting withdrawal criteria, receiving the wrong treatment or dose, or taking prohibited concomitant medications.
03 Subjects with protocol deviations should be listed in the study report and categorized by study site in multicenter studies.


ICH E9 "Statistical Principles for Clinical Trials" stipulates:

For important protocol deviations, it is advisable to specify the time of occurrence, the reasons, and the impact on trial results. The frequency and types of major protocol deviations, missing values, and other issues should be described in the clinical study report, along with an explanation of their potential impact on the study results.
Article illustration

Summary



GCP holds that every deviation and its corresponding corrective and preventive actions must be documented.

ICH-GCP specifies that PD reports must record the PD category, source, severity, date of occurrence, cause, detailed description, and corrective and preventive actions.

Article illustration
Currently, users of the EClinCloud system are typically sponsor/CRO personnel, and the PD reporting workflow applies to CRAs reporting to the sponsor and the ethics committee.

“

In the next issue, we will continue with how client SOPs are presented in CTMS. To be continued—stay tuned for the next issue.





About EClinCloud

EClinCloud is a technology company focused on clinical research and development. It provides an integrated, interconnected all-in-one clinical trial cloud platform (including technology products and offerings such as eCOA, CTMS, eTMF, EDC, RTSM, and RM, as well as solutions such as scale design, scale copyright management, linguistic validation, rater training, and data quality analysis) alongside clinical trial endpoint assessment technologies across therapeutic areas (including central nervous system, ophthalmology, and others). By combining frontier technology with life sciences data, it builds a globally leading "patient-centric" SaaS cloud platform for clinical evidence support, helping domestic and international pharmaceutical companies and research institutions improve R&D efficiency, accelerate the market launch of drugs and medical devices, and benefit countless patients.




Article illustration


Read the original WeChat post

Related reading

WeChat image 2026-11-11_150855_109.pngNews6 min readWorld COPD Day | Imaging Assessment in COPD Clinical ResearchNovember 13-15, 2026. November 18, 2026 marks the 25 World COPD Day, with this year's theme: Early Diagnosis and Management for a Better Life. Chronic Obstructive Pulmonary Disease (COPD) is a preventable and treatable disease characterized by persistent airflow limitation. COPD is closely related to chronic bronchitis and emphysema [1]. We have previously covered COAs for COPD,Article imageNews3 min readAddressing Complex Challenges in Clinical Research: EClinCloud’s Full-Lifecycle AI Enablement Attracts AttentionFrom November 13–15, the 2026 Nucleic Acid Therapy and Intelligent Biomedicine Industry Innovation Conference, academically guided by the Chinese Stroke Association and hosted by the Yuanshu Brain Science Research Center, was held in Fuzhou. Dr. Qin Long, founder and CEO of EClinCloud, was invited to deliver a keynote speech titled “Practice and Application of AI in Clinical Research,” sharing insights on the development trends of AI-enabled new drug R&D and the practice of AI throughout the clinical research process, which attracted enthusiastic attention from the attending guests. 01 Current Landscape of AI-Enabled New Drug R&D: AI is demonstrating application value in multiple segments of new drug R&D, including target discoverySAPA-China 2026 CNS Forum on-site photo 1News3 min readFocusing on CNS Clinical Endpoint Assessment: EClinCloud Shares eCOA and IRC PracticesAt the CNS Forum of the SAPA-China 2026 Pharmaceutical Industry Conference, Zheng Liangyan, Medical Director at EClinCloud, shared approaches to applying eCOA and IRC, covering challenges, regulatory requirements, and practical implementation in central nervous system (CNS) disease clinical research.